) recently announced positive results on Afinitor, from a phase
III trial, BOLERO-3. The study is evaluating Novartis' Afinitor
) Herceptin and vinorelbine for the treatment of women suffering
from HER2 positive (HER2+) advanced breast cancer.
It was observed in the trial (n= 569) that Afinitor plus
Herceptin and vinorelbine significantly extended progression-free
survival (PFS) after prior therapy vis-à-vis placebo plus
Herceptin and vinorelbine.
Novartis will present detailed results at the upcoming annual
meeting of the American Society of Clinical Oncology (ASCO).
Novartis estimates that approximately 140,000 women are
suffering from HER2 positive advanced breast cancer across the
Hence, the successful development and commercialization of
Afinitor for the above-mentioned indication will further boost
the sales potential of the drug. Afinitor generated sales of $797
million in 2013, up 85% year over year.
We remind investors that Afinitor is already approved in the
US and EU (trade name: Votubia) for the treatment of advanced
renal cell carcinoma following vascular endothelial growth
factor-targeted therapy along with other indications.
In 2012, Afinitor received approval from both European
Medicines Agency (EMA) and US Food and Drug Administration (FDA)
for the treatment of HR+/HER2- advanced breast cancer in
) Aromasin, in postmenopausal women whose disease has returned or
progressed even after undergoing treatment with a non-steroidal
We note that Afinitor is an important part of Novartis'
portfolio and are pleased with the company's efforts to expand
Novartis currently carries a Zacks Rank #3 (Hold). Right now,
) looks attractive with a Zacks Rank #1 (Strong Buy).
NOVARTIS AG-ADR (NVS): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
ROCHE HLDG LTD (RHHBY): Get Free Report
SALIX PHARM-LTD (SLXP): Free Stock Analysis
To read this article on Zacks.com click here.